Palo Alto, CA, United States of America

Brian Murphy

This inventor holds 1 USPTO granted patent. Top assignee: Sri International. Active years: 2001.


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2001

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Brian Murphy - Innovator in Tissue-Specific Therapeutics

Introduction

Brian Murphy is a notable inventor based in Palo Alto, CA. He has made significant contributions to the field of biotechnology, particularly in the development of methods and compositions that enhance gene expression under specific conditions.

Latest Patents

Brian Murphy holds a patent for "Tissue specific hypoxia regulated constructs." This patent discloses methods and compositions relating to chimeric genes that contain a tissue-specific promoter and a hypoxia response enhancer element. These elements are operably linked to a selected gene, which may include a reporter gene, therapeutic gene, or deleterious gene. The expression of the selected gene is enhanced in target tissues under hypoxic conditions, such as those encountered during ischemia and reperfusion. The methods and compositions outlined in this patent may be utilized as therapeutics and diagnostics.

Career Highlights

Brian is currently associated with SRI International, where he continues to innovate and contribute to advancements in biotechnology. His work focuses on developing solutions that address critical health challenges.

Collaborations

Brian has collaborated with esteemed colleagues, including Keith A. Webster and Nanette H. Bishopric, who share his commitment to advancing scientific knowledge and therapeutic applications.

Conclusion

Brian Murphy's innovative work in tissue-specific therapeutics exemplifies the impact of biotechnology on healthcare. His contributions continue to pave the way for new diagnostic and therapeutic strategies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…